COCH Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
66.0K
+29.4%
51.0K
+30.8%
39.0K
-48.0%
75.0K
+78.6%
42.0K
Cost of Revenue
244.0K
-12.2%
278.0K
-11.2%
313.0K
+48.3%
211.0K
+3.9%
203.0K
Gross Profit
-178000
+21.6%
-227000
+17.2%
-274000
-101.5%
-136000
+15.5%
-161000
Operating Expenses
5.4M
+0.3%
5.3M
-6.0%
5.7M
-9.0%
6.2M
+22.4%
5.1M
R&D
3.1M
-1.8%
3.1M
-14.0%
3.6M
-20.0%
4.6M
+68.6%
2.7M
SG&A
2.3M
+3.3%
2.2M
+8.2%
2.0M
+20.5%
1.7M
-29.5%
2.4M
Operating Income
-5537000
+0.6%
-5569000
+6.5%
-5959000
+6.7%
-6385000
-21.3%
-5265000
EBITDA
-5462000
+0.6%
-5495000
+6.6%
-5886000
+6.6%
-6305000
-21.5%
-5189000
Net Income
-3932000
+34.3%
-5982000
-37.5%
-4351000
+33.9%
-6586000
-1.6%
-6482000
EPS (Basic)
$-0.50
+28.6%
$-0.70
+12.5%
$-0.80
+70.6%
$-2.72
+23.4%
$-3.55
EPS (Diluted)
$-0.50
+28.6%
$-0.70
+12.5%
$-0.80
+70.6%
$-2.72
+23.4%
$-3.55
Shares (Diluted)
10.4M
+0.3%
10.4M
+50.9%
6.9M
+142.1%
2.8M
+30.3%
2.2M
Envoy Medical (COCH) — Financials